6533b7d5fe1ef96bd1264fc1
RESEARCH PRODUCT
NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer
J. CastilloM. Belda MoscardòT. Fleitas KanonnikoffB. García-micóSusana RosellóValentina GambardellaF. Gimeno-valienteN. TarazonaP. TolosaDesamparados RodaA. CervantesMarisol Huertasubject
0301 basic medicinebusiness.industryCancerHematologymedicine.diseaseNrf2 activation03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCancer researchMedicineAnti her2businessProtein kinase B030217 neurology & neurosurgeryPI3K/AKT/mTOR pathwayyear | journal | country | edition | language |
---|---|---|---|---|
2018-10-01 | Annals of Oncology |